About

Professor Ziyaur Rahman is associated with the Texas A&M Irma Lerma Rangel College of Pharmacy. The provided page text does not include specific details about his research focus, background, or key contributions. Therefore, a detailed professional biography cannot be extracted from the given information.

Research topics

• Chemistry
• Computer Science
• Pharmacology
• Medicine
• Organic chemistry
• Nanotechnology
• Chromatography
• Biochemistry
• Nuclear chemistry
• Engineering
• Materials science
• Process engineering
• Chemical engineering
• Business
• Bioinformatics
• Internal medicine
• Risk analysis (engineering)

Selected publications

• Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution

  AAPS PharmSciTech · 2026-04-09

  articleOpen accessSenior authorCorresponding

  The objectives of the present work were to study the effect of patient-in use and accelerated storage conditions on critical quality attributes (CQAs) of FDA approved varenicline tartrate (VRT) products. Four products (V1, V2, V3 and V4) of VRT were stored at 30 °C/75% RH and 40 °C/75% RH for three and six months, respectively, and tested periodically for nitrite, impurities (N-nitroso varenicline, N-formyl varenicline and N-methyl varenicline), assay, dissolution and solid-state of the drug. Nitrite content decreased while N-nitroso varenicline increased with storage temperature and duration. Initial nitrite value range was 9.3 ± 2.3 to 31.0 ± 9.3 ng/tablet that decreased to 1.7 ± 0.3 to 8.1 ± 5.4 ng/tablet after six months storage at 40 °C/75%. N-nitroso varenicline, N-formyl varenicline and N-methyl varenicline content ranged from 0-31.0 ± 11, 75 ± 9.1 to 5530.0 ± 1.2, and 7.0 ± 0.3 to 1633.2 ± 55.8 ng/tablet after storage, respectively. Polymorphic forms present in V1 and V4 were A and B, respectively, while products V2 and V3 contained amorphous form of the drug. No change in solid state was observed in the products except a decrease in crystallinity of almost 30% after storge. All products completely dissolved > 85% drug in 15 min before storage. V1 and V4 showed no significant change in dissolution while product V2 and V3 showed significant decrease in the dissolution. The dissolved drug was 33.6 ± 0.5 and 34.2 ± 0.7% in 30 min from V2 and V3 after storage, respectively. In summary, tested products showed differential effects of stability conditions on the CQAs and some of the attributes were critically diminished that need further investigation.

  PublisherDOI

• Design of SLS 3D-printed pediatric combination printlets of lamivudine and tenofovir disoproxil fumarate by understanding the impact of formulation and process variables on flow, spectral, thermal and performance characteristics

  International Journal of Pharmaceutics · 2025-07-15 · 2 citations

  articleOpen access
  PublisherOA PDFDOI

• Additive manufacturing and criteria to fabricate bioinks

  Elsevier eBooks · 2025-01-01

  book-chapterSenior author
  PublisherDOI

• Mechanism of microglia-mediated neuroinflammation, associated cognitive dysfunction, and therapeutic updates in Alzheimer's disease

  hLife · 2025-01-11 · 21 citations

  articleOpen access

  Alzheimer's disease (AD) and associated cognitive dysfunction are major healthcare challenges globally. Various mechanisms of pathogenesis and signaling molecules have been studied for their plausible role in disease initiation and progression. Neuroinflammation has been considered a major hallmark of AD. Amyloid beta (Aβ), hyperphosphorylated tau protein, and formed neurofibrillary tangles (NFT) are positively correlated with neuroinflammation. Microglial activation was found to be a key contributor to neuroinflammation, AD pathogenesis, and progression. The mechanism of microglial activation has been studied in detail, and looking into its pivotal role in disease etiology, various drugs have been developed, and many are in the clinical phases of development. These drugs either inhibit the microglial activation or neuroinflammatory event postmicroglial activation. Considering these facts, in the present study, we herein discuss the mechanism of microglial activation and the mechanism of neuroinflammation related to microglial activation and dementia. Here we also discussed the various drugs that either act at tau protein or mitigate neuroinflammation, along with their status in clinical trials. In brief, this review provides an in-depth mechanism of microglial activation and updates on drugs that can inhibit this activation, leading to significant anti-Alzheimer effect and mitigation of cognitive dysfunction. • Microglial activation has a significant impact on the pathogenesis of Alzheimer's disease. • Understanding the molecular mechanism of microglial activation is important to design, develop, or repurpose the drugs. • Various natural products or small molecules have shown a significant positive impact on microglial-activated Alzheimer's disease. • Various clinical trials are under different phases, and in the coming time, drugs might change the landscape of Alzheimer's disease treatment.

  PublisherDOI

• Real-Time Monitoring of Selective Laser Sintering 3d Printing Process for Lamivudine Content Quantification in the Printlets: A Modern Solution to a Modern Problem

  SSRN Electronic Journal · 2025-01-01

  preprintOpen access
  PublisherDOI

• Effects of Particle Size Distribution on the Performance of Selective Laser Sintered Pharmaceutical Printlets

  SSRN Electronic Journal · 2025-01-01

  preprintOpen access
  PublisherDOI

• Development and Characterization of Printlets of Lamivudine for Pediatric Patients Using Selective Laser Sintering

  Pharmaceuticals · 2025-03-01 · 2 citations

  articleOpen access

  Background: Lamivudine is widely used alone or in combination with other anti-HIV drugs in the infant to adolescent age groups of pediatric populations. Compounding of medications is frequently used for pediatric patients. However, many issues have been reported for the compounded formulation such as assay, stability, safety, and efficacy. Three-dimensional printing can overcome these issues. Objective: The aim of this study was to understand the effect of process and formulation variables on lamivudine printlets for pediatric populations using selective laser sintering. Methods: The Plackett–Burman screening design was used to prepare 12 formulations to study six variables, namely, laser scanning speed (130–150 °C), surface temperature (105–120 °C), chamber temperature (250–350 mm/s), sucrose (0–30%), hydroxypropyl methylcellulose (0–42%), and Kollidon® CL-M (0–5%). The formulations were tested for dissolution, disintegration, hardness, assay, X-ray diffraction, differential scanning calorimetry, stability, and pharmacokinetics in Sprague Dawley rats. Results: The assay of the printlet formulations varied between 93.1 and 103.5% and the disintegration time was 2.8 ± 1.2 (F1) to 43.7 ± 2.7 (F10) s. Due to high surface temperatures, the unsintered powder in the printing chamber experienced significant changes in crystallinity. No statistical significance was observed between the pharmacokinetic parameters of the printlets and commercial tablets (p > 0.05). The maximum plasma concentration (Cmax), time to reach maximum plasma concentration (Tmax), and area under the curve (AUC) of the printlets and commercial tablets were 295.5 ± 33.0 and 305.0 ± 70.1 ng/mL, 0.5 ± 0.0 and 1.0 ± 0.8 h, and 1414.1 ± 174.0 and 1987.2 ± 700.5 ng.h/mL, respectively. Conclusions: In summary, fast-disintegrating and dissolving 3D printed lamivudine was found to be bioequivalent to commercial formulation of lamivudine. Thus, it is a viable method for dispensing personalized lamivudine printlets for pediatric populations.

  PublisherOA PDFDOI

• Patient in-use, room temperature and accelerated conditions stability evaluation of FDA approved clopidogrel hydrogen sulfate products

  International Journal of Pharmaceutics · 2025-03-29 · 2 citations

  article
  PublisherDOI

• Real-time monitoring of selective laser sintering 3D printing process for lamivudine content quantification in the printlets: a modern solution to a modern problem

  International Journal of Pharmaceutics · 2025-09-05 · 2 citations

  articleOpen access
  PublisherOA PDFDOI

• A Comparative Study in Metformin Tablet Quality Assessment: LC‐MS and LC‐MS/MS Method Quantification of N‐Nitroso‐Dimethylamine in the Presence of Dimethyl Formamide

  International Journal of Analytical Chemistry · 2025-01-01

  articleOpen accessSenior authorCorresponding

  N‐nitroso‐dimethylamine (NDMA, acceptable daily intake limit 96 ng/day), a probable human carcinogenic impurity, has been reported in metformin formulations. In some cases, it is difficult to accurately detect its presence due to suboptimal extraction technique(s), coelution of other probable human carcinogenic impurities such as dimethyl formamide (DMF) and/or ionization suppression in mass spectroscopic measurements. In this study, we provided a simple method to address DMF artifact using an affordable high‐performance liquid chromatography coupled with a single‐stage mass spectrometer. The results were further confirmed by dual‐stage mass spectrometry. The two developed methods can simultaneously identify NDMA in the presence of DMF with good linear range from 10 to 100 ng/mL ( r 2 = 0.971) and 1 to 10 ng/mL ( r 2 = 0.994), respectively. The accuracy, expressed as % recovery, was close to 100% with overall precision (%RSD) < 8. The two methods were linear in the presence of 100 ng/mL DMF with r 2 = 0.996 and 0.98, respectively. Five commercial formulations of metformin tablets showed traces of NDMA below the regulatory limit (0–12 ± 0.2 ng/tablet) but appreciable amounts of DMF (50–653.5 ng/tablet), still lower than the permissible daily exposure limit (8.8 mg/day) based on the maximum daily dose of metformin (5 tablets, 2500 mg). Both methods proved reliable and informative in the quality control of the NDMA content in metformin tablets and provided reciprocal verification of results.

  PublisherOA PDFDOI

Frequent coauthors

• Mansoor A. Khan

  Hayatabad Medical Complex

  283 shared

• Eman M. Mohamed

  Texas A&M Health Science Center

  160 shared

• Sathish Dharani

  Texas A&M Health Science Center

  130 shared

• Sogra F. Barakh Ali

  73 shared

• Tahir Khuroo

  Texas A&M Health Science Center

  65 shared

• Hamideh Afrooz

  Texas A&M University

  57 shared

• Akhtar Siddiqui

  Center for Drug Evaluation and Research

  49 shared

• Naseem A. Charoo

  48 shared

Labs

• Pharmaceutical SciencesPI

Education

• Ph.D. (Pharmaceutics), Pharmaceutics

  Jamia Hamdard Faculty of Pharmacy

  2005

• M.S. (Pharmaceutics), Pharmaceutics

  Jamia Hamdard Faculty of Pharmacy

  2002

• B.S. (Pharmacy), Pharmacy

  Jamia Hamdard Faculty of Pharmacy

  2000

Awards & honors

• Presidential Impact Fellow